10-Q 1 cogt-20230930.htm 10-Q 10-Q
--12-310001622229falseQ3http://www.cogentbio.com/20230930#ChangeInFairValueOfContingentValueRightLiabilityhttp://www.cogentbio.com/20230930#ChangeInFairValueOfContingentValueRightLiability0001622229us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001622229us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001622229srt:MaximumMembercogt:GuggenheimSecuritiesLLCMember2022-05-060001622229us-gaap:CommonStockMember2022-09-300001622229us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001622229cogt:ContingentValueRightMember2023-09-300001622229us-gaap:OverAllotmentOptionMemberus-gaap:CommonStockMember2022-06-130001622229us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001622229us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-3000016222292022-09-300001622229us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembersrt:MaximumMembercogt:BOXRPlatformMembercogt:SOTIOMember2020-08-280001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-01-012023-03-310001622229cogt:TwoThousandEighteenEmployeeStockPurchasePlanMember2023-01-012023-01-010001622229us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001622229us-gaap:RetainedEarningsMember2023-01-012023-03-310001622229us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001622229cogt:CommonStockUnderwrittenPublicOfferingMember2022-01-012022-09-300001622229us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001622229cogt:ContingentValueRightMember2022-12-310001622229cogt:TimeBasedStockOptionsMember2022-07-012022-09-300001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2021-12-310001622229us-gaap:CommonStockMember2023-04-012023-06-300001622229us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001622229us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001622229cogt:UstreasuryBillsAndNotesSecuritiesDueAfterOneThroughFiveYearsMember2023-09-300001622229us-gaap:RetainedEarningsMember2022-03-310001622229us-gaap:CommonStockMember2022-07-012022-09-300001622229cogt:TwoThousandEighteenStockOptionAndIncentivePlanMember2023-09-3000016222292022-07-012022-09-300001622229srt:MaximumMemberus-gaap:SeriesAPreferredStockMember2023-09-3000016222292023-01-012023-03-310001622229cogt:ContingentValueRightMember2020-11-012020-11-300001622229cogt:ContingentValueRightMember2023-01-012023-03-310001622229cogt:SeriesANonVotingConvertiblePreferredStockMember2022-12-310001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-06-300001622229cogt:CommonStockUnderwrittenPublicOfferingMember2023-01-012023-09-300001622229us-gaap:EmployeeStockMember2023-01-012023-09-300001622229us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001622229cogt:TimeBasedStockOptionsMember2023-01-012023-09-300001622229cogt:TwoThousandEighteenEmployeeStockPurchasePlanMember2018-03-2800016222292022-03-310001622229cogt:ContingentValueRightMember2021-02-012021-02-280001622229us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001622229us-gaap:OverAllotmentOptionMember2023-06-012023-06-300001622229us-gaap:RetainedEarningsMember2022-01-012022-03-310001622229us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001622229us-gaap:AdditionalPaidInCapitalMember2022-06-300001622229us-gaap:OverAllotmentOptionMember2022-06-130001622229us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001622229us-gaap:CommonStockMember2023-01-012023-03-310001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-03-310001622229us-gaap:AdditionalPaidInCapitalMember2023-09-3000016222292022-01-012022-03-310001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-07-012022-09-300001622229cogt:ContingentValueRightMember2022-01-012022-12-310001622229cogt:TwoThousandTwentyInducementPlanMember2020-10-220001622229us-gaap:CommonStockMember2021-12-310001622229us-gaap:CommonStockMember2023-07-012023-09-300001622229us-gaap:SeriesAPreferredStockMember2023-09-3000016222292022-12-310001622229us-gaap:CommonStockMember2022-12-310001622229cogt:PerformanceBasedRestrictedStockUnitsPsusMember2023-09-3000016222292023-04-012023-06-300001622229us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001622229cogt:PlexxikonLicenseAgreementMember2023-09-300001622229us-gaap:RetainedEarningsMember2021-12-310001622229us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001622229us-gaap:RetainedEarningsMember2023-03-310001622229cogt:TwoThousandEighteenEmployeeStockPurchasePlanMember2023-09-300001622229us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001622229us-gaap:CommonStockMember2022-06-130001622229cogt:PlexxikonLicenseAgreementMember2022-06-300001622229us-gaap:FairValueMeasurementsRecurringMember2023-09-3000016222292022-06-300001622229srt:MaximumMembercogt:TwoThousandEighteenEmployeeStockPurchasePlanMember2018-03-2800016222292023-07-012023-09-300001622229cogt:PerformanceBasedRestrictedStockUnitsMember2023-07-012023-09-300001622229cogt:SeriesANonVotingConvertiblePreferredStockMember2023-09-300001622229us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001622229cogt:GuggenheimSecuritiesLLCMember2023-01-012023-09-300001622229us-gaap:CommonStockMember2022-01-012022-03-3100016222292022-01-012022-09-300001622229us-gaap:EmployeeStockMember2022-01-012022-09-3000016222292023-03-310001622229cogt:PerformanceBasedRestrictedStockUnitsMember2023-01-012023-09-300001622229cogt:TwoThousandEighteenStockOptionAndIncentivePlanMember2023-06-072023-06-070001622229us-gaap:SeriesAPreferredStockMember2020-07-062023-09-300001622229us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001622229us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001622229us-gaap:CommonStockMember2022-06-300001622229us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001622229srt:MaximumMember2022-05-062022-05-060001622229cogt:TimeBasedStockOptionsMember2023-07-012023-09-300001622229us-gaap:AdditionalPaidInCapitalMember2023-06-300001622229cogt:ContingentValueRightMember2021-12-310001622229us-gaap:FairValueMeasurementsRecurringMember2022-12-3100016222292020-07-060001622229us-gaap:CommonStockMember2023-03-310001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-03-3100016222292022-01-012022-12-310001622229us-gaap:OverAllotmentOptionMember2022-06-132022-06-130001622229us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-01-012022-03-310001622229cogt:UndesignatedPreferredStockMember2022-12-310001622229us-gaap:CommonStockMember2022-04-012022-06-300001622229us-gaap:CommonStockMember2023-01-012023-09-300001622229us-gaap:AdditionalPaidInCapitalMember2021-12-310001622229cogt:UndesignatedPreferredStockMember2023-09-300001622229us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001622229cogt:UsTreasuryBillsAndNotesSecuritiesMember2023-09-300001622229srt:MinimumMembercogt:TwoThousandEighteenStockOptionAndIncentivePlanMember2023-02-012023-02-2800016222292023-06-300001622229cogt:PerformanceBasedRestrictedStockUnitsPsusMember2023-01-012023-09-300001622229us-gaap:EmployeeStockOptionMember2023-09-300001622229us-gaap:RetainedEarningsMember2023-09-300001622229us-gaap:CommonStockMember2023-06-300001622229us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001622229us-gaap:AdditionalPaidInCapitalMember2023-03-310001622229srt:MaximumMemberus-gaap:OverAllotmentOptionMember2022-06-130001622229us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001622229us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001622229srt:MinimumMemberus-gaap:SeriesAPreferredStockMember2023-09-300001622229us-gaap:CommonStockMember2020-07-062023-09-3000016222292023-01-012023-09-3000016222292022-04-012022-06-300001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-09-300001622229us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001622229us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-04-012022-06-300001622229us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001622229us-gaap:CommonStockMember2023-09-300001622229cogt:UsTreasuryBillsAndNotesSecuritiesMember2022-12-310001622229us-gaap:AdditionalPaidInCapitalMember2022-12-310001622229us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001622229us-gaap:RetainedEarningsMember2022-12-310001622229us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-3000016222292023-11-030001622229srt:MaximumMembercogt:TwoThousandEighteenStockOptionAndIncentivePlanMember2023-02-012023-02-280001622229us-gaap:SeriesAPreferredStockMember2023-01-012023-09-300001622229cogt:TwoThousandTwentyInducementPlanMember2020-11-050001622229cogt:UnderwrittenPublicOfferingMember2022-04-012022-06-300001622229us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembercogt:BOXRPlatformMembercogt:SOTIOMember2020-08-280001622229us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001622229cogt:TimeBasedStockOptionsMember2022-01-012022-09-300001622229srt:MaximumMember2023-01-012023-09-300001622229us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001622229us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001622229us-gaap:EmployeeStockMember2023-07-012023-09-300001622229us-gaap:OverAllotmentOptionMember2023-06-300001622229us-gaap:AdditionalPaidInCapitalMember2022-03-3100016222292023-09-300001622229cogt:ContingentValueRightMember2020-07-060001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-06-300001622229us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001622229us-gaap:OverAllotmentOptionMember2023-09-3000016222292023-08-062023-08-060001622229cogt:TwoThousandEighteenStockOptionAndIncentivePlanMember2018-03-272018-03-270001622229us-gaap:RetainedEarningsMember2022-04-012022-06-300001622229srt:MaximumMembercogt:PlexxikonLicenseAgreementMember2020-07-012020-07-300001622229us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001622229cogt:ContingentValueRightMember2023-01-012023-09-300001622229us-gaap:SeriesAPreferredStockMember2022-01-012022-09-300001622229us-gaap:RetainedEarningsMember2023-06-300001622229cogt:TwoThousandEighteenStockOptionAndIncentivePlanMember2018-03-270001622229cogt:UnderwrittenPublicOfferingMember2023-04-012023-06-300001622229us-gaap:RetainedEarningsMember2022-06-300001622229us-gaap:RetainedEarningsMember2023-07-012023-09-300001622229cogt:PlexxikonLicenseAgreementMember2023-01-012023-09-300001622229us-gaap:RetainedEarningsMember2022-07-012022-09-300001622229us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001622229cogt:TwoThousandTwentyInducementPlanMember2023-09-300001622229us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001622229us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001622229us-gaap:EmployeeStockMember2022-07-012022-09-300001622229us-gaap:RetainedEarningsMember2022-09-300001622229us-gaap:RetainedEarningsMember2023-04-012023-06-300001622229us-gaap:CommonStockMember2022-03-310001622229srt:MaximumMembercogt:TwoThousandEighteenEmployeeStockPurchasePlanMember2018-03-282018-03-2800016222292021-12-310001622229us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001622229cogt:TwoThousandEighteenStockOptionAndIncentivePlanMember2023-02-012023-02-280001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-09-300001622229cogt:TwoThousandEighteenStockOptionAndIncentivePlanMember2023-01-012023-01-010001622229us-gaap:AdditionalPaidInCapitalMember2022-09-300001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2023-07-012023-09-300001622229cogt:SeriesANonVotingConvertiblePreferredStockMemberus-gaap:PreferredStockMember2022-12-31cogt:Securityxbrli:purexbrli:sharesiso4217:USDiso4217:USDxbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38443

 

Cogent Biosciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

46-5308248

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification Number)

 

275 Wyman Street, 3rd Floor

Waltham, Massachusetts

 

02451

(Address of principal executive offices)

 

(Zip code)

(617) 945-5576

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 Par Value

 

COGT

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 

As of November 3, 2023, there were 86,124,249 shares of the registrant’s Common Stock, $0.001 par value per share, outstanding.

 

 

 


 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and financial performance. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “might,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “seek,” “would” or “continue,” or the negative of these terms or other similar expressions. The forward looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in Item 1A. “Risk Factors.” Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Some of the key factors that could cause actual results to differ from our expectations include:

the potential impacts of raising additional capital, including dilution to our existing stockholders, restrictions on our operations or requirements that we relinquish rights to our technologies or product candidates;
the success, cost, and duration of our product development activities and clinical trials, including the enrollment rates in our clinical trials;
the timing of our planned regulatory submissions to the FDA for our bezuclastinib product candidate and any other product candidates we may develop;
our ability to obtain and maintain regulatory approval for our bezuclastinib product candidate and any other product candidates we may develop, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate;
the potential for our identified research priorities to advance our bezuclastinib product candidate or for our teams to discover and develop additional product candidates;
the ability to license additional intellectual property rights relating to our bezuclastinib product candidate or future product candidates from third-parties and to comply with our existing or future license agreements and/or collaboration agreements;
our ability to commercialize our bezuclastinib product candidate and future product candidates in light of the intellectual property rights of others;
our ability to obtain funding for our operations, including funding necessary to complete further discovery, development and commercialization of our existing and future product candidates;
the scalability and commercial viability of our manufacturing methods and processes;
the commercialization of our product candidates, if approved;
our ability to attract collaborators with development, regulatory, and commercialization expertise;
future agreements with third parties in connection with the commercialization of our product candidates and any other approved product;
the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
the rate and degree of market acceptance of our product candidates;
the pricing and reimbursement of our product candidates, if approved;
regulatory developments in the United States and foreign countries;

i


 

the impact of adverse business and economic conditions including inflationary pressures, general economic slowdown or a recession, increasing interest rates, changes in monetary policy, banking institution instability and the prospect of a shutdown of the U.S. federal government;
our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
the development and success of competing therapies that are or may be under development in clinical trials or that are or may become available commercially;
our ability to attract and retain key scientific and management personnel;
the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;
our use of the proceeds from the private placements, sales of our preferred stock and public offerings of our common stock from time to time;
our expectations regarding our ability to obtain and maintain intellectual property protection for our bezuclastinib product candidate and future product candidates; and
business interruptions resulting from public health crises, which could cause a disruption to the development of our product candidates and adversely impact our business.

While we may elect to update these forward-looking statements at some point in the future, whether as a result of any new information, future events, or otherwise, we have no current intention of doing so except to the extent required by applicable law.

ii


 

Cogent Biosciences, Inc.

Table of Contents

 

Page

 

PART I—FINANCIAL INFORMATION

 

Item 1.

Financial Statements (Unaudited)

1

 

Condensed Consolidated Balance Sheets

1

 

Condensed Consolidated Statements of Operations and Comprehensive Loss

2

 

Condensed Consolidated Statements of Stockholders’ Equity

3

 

Condensed Consolidated Statements of Cash Flows

5

 

Notes to Unaudited Condensed Consolidated Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

27

Item 4.

Controls and Procedures

27

 

PART II—OTHER INFORMATION

 

Item 1.

Legal Proceedings

28

Item 1A.

Risk Factors

28

Item 2.

Recent Sales of Unregistered Securities and Use of Proceeds

28

Item 3.

Defaults Upon Senior Securities

28

Item 4.

Mine Safety Disclosures

28

Item 5.

Other Information

28

Item 6.

Exhibits

29

Signatures

30

 

iii


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

COGENT BIOSCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

(unaudited)

 

 

 

September 30,

 

 

December 31,

 

 

 

2023

 

 

2022

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

86,810

 

 

$

139,886

 

Short-term marketable securities

 

 

192,231

 

 

 

119,390

 

Prepaid expenses and other current assets

 

 

6,912

 

 

 

4,435

 

Restricted cash

 

 

 

 

 

1,255

 

Total current assets

 

 

285,953

 

 

 

264,966

 

Long-term marketable securities

 

 

33,794

 

 

 

 

Operating lease, right-of-use asset

 

 

22,194

 

 

 

23,316

 

Property and equipment, net

 

 

8,643

 

 

 

7,783

 

Other assets

 

 

4,862

 

 

 

4,745

 

Total assets

 

$

355,446

 

 

$

300,810

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

9,868

 

 

$

5,842

 

Accrued expenses and other current liabilities

 

 

23,507

 

 

 

17,884

 

CVR liability (Note 3)

 

 

 

 

 

1,700

 

Operating lease liability

 

 

1,344

 

 

 

1,423

 

Total current liabilities

 

 

34,719

 

 

 

26,849

 

Operating lease liability, net of current portion

 

 

17,829

 

 

 

18,226

 

Total liabilities

 

 

52,548

 

 

 

45,075

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.001 par value; 9,000,000 shares authorized; no shares issued
   or outstanding

 

 

 

 

 

 

Series A non-voting convertible preferred stock, $0.001 par value; 1,000,000 
   shares authorized;
74,465 and 81,050 shares issued and outstanding at
   September 30, 2023 and December 31, 2022, respectively

 

 

60,035

 

 

 

65,830

 

Common stock, $0.001 par value; 150,000,000 shares authorized; 86,124,249
   shares and
69,893,434 shares issued and outstanding at September 30, 2023 and
   December 31, 2022, respectively

 

 

86

 

 

 

70

 

Additional paid-in capital

 

 

792,208

 

 

 

601,153

 

Accumulated other comprehensive loss

 

 

(172

)

 

 

(104

)

Accumulated deficit

 

 

(549,259

)

 

 

(411,214

)

Total stockholders’ equity

 

 

302,898

 

 

 

255,735

 

Total liabilities and stockholders’ equity

 

$

355,446

 

 

$

300,810

 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

1


 

COGENT BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share amounts)

(unaudited)

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development

$

50,127

 

 

$

29,936

 

 

$

125,036

 

 

$

84,885

 

General and administrative

 

9,453

 

 

 

6,885

 

 

 

24,866

 

 

 

19,209

 

Total operating expenses

 

59,580

 

 

 

36,821

 

 

 

149,902

 

 

 

104,094

 

Loss from operations

 

(59,580

)

 

 

(36,821

)

 

 

(149,902

)

 

 

(104,094

)

Other income:

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

4,198

 

 

 

1,500

 

 

 

9,207

 

 

 

1,879

 

Other income, net

 

 

 

 

259

 

 

 

950

 

 

 

1,592

 

Change in fair value of CVR liability

 

 

 

 

 

 

 

1,700

 

 

 

 

Total other income, net

 

4,198

 

 

 

1,759

 

 

 

11,857

 

 

 

3,471

 

Net loss

$

(55,382

)

 

$

(35,062

)

 

$

(138,045

)

 

$

(100,623

)

Net loss per share attributable to common stockholders, basic and diluted

$

(0.64

)

 

$

(0.50

)

 

$

(1.79

)

 

$

(1.84

)

Weighted average common shares outstanding, basic and diluted

 

86,165,951

 

 

 

69,576,359

 

 

 

77,274,580

 

 

 

54,780,041

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

Net loss

$

(55,382

)

 

$

(35,062

)

 

$

(138,045

)

 

$

(100,623

)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

Net unrealized losses on marketable securities

 

(75

)

 

 

(163

)

 

 

(68

)

 

 

(163

)

Total other comprehensive loss

 

(75

)

 

 

(163

)

 

 

(68

)

 

 

(163

)

Comprehensive loss

$

(55,457

)

 

$

(35,225

)

 

$

(138,113

)

 

$

(100,786

)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

2


 

COGENT BIOSCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

(unaudited)

 

 

 

Series A Non-Voting
Convertible Preferred
Stock

 

 

Common Stock

 

 

Additional
Paid-in

 

 

Accumulated Other Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Income (Loss)

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2022

 

 

81,050

 

 

$

65,830

 

 

 

69,893,434

 

 

$

70

 

 

$

601,153

 

 

$

(104

)

 

$

(411,214

)

 

$

255,735

 

Conversion of Series A non-voting preferred
   stock into common stock

 

 

(4,000

)

 

 

(3,520

)

 

 

1,000,000

 

 

 

1

 

 

 

3,519

 

 

 

 

 

 

 

 

 

 

Issuance of common stock under Employee
   Stock Purchase Plan

 

 

 

 

 

 

 

 

39,228

 

 

 

 

 

 

313

 

 

 

 

 

 

 

 

 

313

 

Issuance of common stock upon exercise of
   stock options

 

 

 

 

 

 

 

 

14,128

 

 

 

 

 

 

132

 

 

 

 

 

 

 

 

 

132

 

Unrealized gains on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

120

 

 

 

 

 

 

120

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

5,850

 

 

 

 

 

 

 

 

 

5,850

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(38,587

)

 

 

(38,587

)

Balances at March 31, 2023

 

 

77,050

 

 

$

62,310

 

 

 

70,946,790

 

 

$

71

 

 

$

610,967

 

 

$

16

 

 

$

(449,801

)

 

$

223,563

 

Issuance of common stock in underwritten public
   offering, net of offering costs of $
10.7 million

 

 

 

 

 

 

 

 

14,375,000

 

 

 

14

 

 

 

161,775

 

 

 

 

 

 

 

 

 

161,789

 

Issuance of common stock upon exercise of
   stock options

 

 

 

 

 

 

 

 

12,375

 

 

 

 

 

 

102

 

 

 

 

 

 

 

 

 

102

 

Unrealized losses on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

(113

)

 

 

 

 

 

(113

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7,163

 

 

 

 

 

 

 

 

 

7,163

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

 

 

 

(44,076

)

 

 

(44,076

)

Balances at June 30, 2023

 

 

77,050

 

 

$

62,310

 

 

 

85,334,165

 

 

$

85

 

 

$

780,007

 

 

$

(97

)

 

$

(493,877

)

 

$

348,428

 

Conversion of Series A non-voting preferred
   stock into common stock

 

 

(2,585

)

 

 

(2,275

)

 

 

646,250

 

 

 

1

 

 

 

2,274

 

 

 

 

 

 

 

 

 

 

Issuance of common stock upon exercise of
   stock options

 

 

 

 

 

 

 

 

97,184

 

 

 

 

 

 

731

 

 

 

 

 

 

 

 

 

731

 

Issuance of common stock under Employee
   Stock Purchase Plan

 

 

 

 

 

 

 

 

46,650

 

 

 

 

 

 

439

 

 

 

 

 

 

 

 

 

439

 

Unrealized losses on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(75

)

 

 

 

 

 

(75

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

8,757

 

 

 

 

 

 

 

 

 

8,757

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(55,382

)

 

 

(55,382

)

Balances at September 30, 2023

 

 

74,465

 

 

$

60,035

 

 

 

86,124,249

 

 

$

86

 

 

$

792,208

 

 

$

(172

)

 

$

(549,259

)

 

$

302,898

 

 

3


 

 

 

 

 

Series A Non-Voting

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Convertible Preferred
Stock

 

 

Common Stock

 

 

Additional
Paid-in

 

 

Accumulated
Other Comprehensive

 

 

Accumulated

 

 

Total
Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balances at December 31, 2021

 

 

103,289

 

 

$

85,400

 

 

 

43,805,922

 

 

$

44

 

 

$

399,713

 

 

$

 

 

$

(270,973

)

 

$

214,184

 

Conversion of Series A non-voting preferred
   stock into common stock

 

 

(7,955

)

 

 

(7,000

)

 

 

1,988,750

 

 

 

2

 

 

 

6,998

 

 

 

 

 

 

 

 

 

 

Issuance of common stock to settle CVR
   liability

 

 

 

 

 

 

 

 

18,995

 

 

 

 

 

 

129

 

 

 

 

 

 

 

 

 

129

 

Issuance of common stock for services

 

 

 

 

 

 

 

 

5,599

 

 

 

 

 

 

9

 

 

 

 

 

 

 

 

 

9

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4,175

 

 

 

 

 

 

 

 

 

4,175

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(30,634

)

 

 

(30,634

)

Balances at March 31, 2022

 

 

95,334

 

 

$

78,400

 

 

 

45,819,266

 

 

$

46

 

 

$

411,024

 

 

$

-

 

 

$

(301,607

)

 

$

187,863

 

Issuance of common stock and pre-funded
   warrants in underwritten public offering,
   net of offering costs of $
10.8 million

 

 

 

 

 

 

 

 

17,899,698

 

 

 

18

 

 

 

161,897

 

 

 

 

 

 

 

 

 

161,915

 

Conversion of Series A non-voting preferred
   stock into common stock

 

 

(7,955

)

 

 

(7,000

)

 

 

1,988,750

 

 

 

2

 

 

 

6,998

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4,534

 

 

 

 

 

 

 

 

 

4,534

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(34,927

)

 

 

(34,927

)

Balances at June 30, 2022

 

 

87,379

 

 

$

71,400

 

 

 

65,707,714

 

 

$

66

 

 

$

584,453

 

 

$

-

 

 

$

(336,534

)

 

$

319,385

 

Conversion of Series A non-voting preferred
   stock into common stock

 

 

(6,329

)

 

 

(5,570

)

 

 

1,582,250

 

 

 

2

 

 

 

5,568

 

 

 

 

 

 

 

 

 

 

Pre-funded warrant exercise

 

 

 

 

 

 

 

 

2,424,242

 

 

 

2

 

 

 

22

 

 

 

 

 

 

 

 

 

24

 

Issuance of common stock under Employee
   Stock Purchase Plan

 

 

 

 

 

 

 

 

30,005

 

 

 

 

 

 

222

 

 

 

 

 

 

 

 

 

222

 

Issuance of common stock upon exercise of
   stock options

 

 

 

 

 

 

 

 

113,761

 

 

 

 

 

 

914

 

 

 

 

 

 

 

 

 

914

 

Net unrealized losses on marketable securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(163

)

 

 

 

 

 

(163

)

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4,622

 

 

 

 

 

 

 

 

 

4,622

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(35,062

)

 

 

(35,062

)

Balances at September 30, 2022